PFBT
ZVRA icon

Parkside Financial Bank & Trust’s Zevra Therapeutics ZVRA Stock Holding History

Parkside Financial Bank & Trust’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$560 Hold
60
– – ﹤0.01% 2549
2025
Q4 		$538 Hold
60
– – ﹤0.01% 2559
2025
Q3 		$571 Hold
60
– – ﹤0.01% 2509
2025
Q2 		$529 Buy
+60
New +$487 ﹤0.01% 2517

Other funds holding ZVRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Parkside Financial Bank & Trust's ZVRA Position: Q1 2026 in Review

Parkside Financial Bank & Trust held its Zevra Therapeutics (ZVRA) position steady in Q1 2026 at 60 shares worth $560. The position accounts for ﹤0.01% of the portfolio, ranked #2549.

Parkside Financial Bank & Trust first reported a position in ZVRA in Q2 2025 and has held it in 4 quarters since. The position peaked at $571 in Q3 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • Parkside Financial Bank & Trust held 60 shares of Zevra Therapeutics worth $560 as of Q1 2026.
  • Parkside Financial Bank & Trust left its Zevra Therapeutics share count unchanged in Q1 2026.
  • Zevra Therapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q1 2026, its #2549 holding.
  • Parkside Financial Bank & Trust first reported a position in Zevra Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Parkside Financial Bank & Trust's Zevra Therapeutics position peaked at $571 in Q3 2025.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q1 2026, filed 13 May 2026.